The gene expression profiles of human breast tumours fall into three main groups that have been called luminal, basal and either HER2-enriched or molecular apocrine. To escape from the circularity of descriptive classifications based purely on gene signatures I describe a biological classification based on a model of the mammary lineage. In this model I propose that the third group is a tumour derived from a mammary hormone-sensing cell that has undergone apocrine metaplasia. I first split tumours into hormone sensing and milk secreting cells based on the expression of transcription factors linked to cell identity (the luminal progenitor split), then split the hormone sensing group into luminal and apocrine groups based on oestrogen receptor activity (the luminal-apocrine split). I show that the luminalapocrine-basal (LAB) approach can be applied to microarray data (186 tumours) from an EORTC trial and to RNA-seq data from TCGA (674 tumours), and compare results obtained with the LAB and PAM50 approaches. Unlike pure signature-based approaches, classification based on an explicit biological model has the advantage that it is both refutable and capable of meaningful improvement as biological understanding of mammary tumorigenesis improves.
INTRODUCTION
Early breast cancers are traditionally classified by histology, tumour size, axillary nodal status, grade, Ki67, expression of steroid hormone receptors (oestrogen receptor alpha [ER] and progesterone receptor [PR] ) and amplification of human epidermal growth factor receptor 2 (HER2/ERBB2). Together they allow oncologists to select patients for treatment with systemic medical therapies: chemotherapy, drugs targeting ER or oestrogen synthesis, and drugs targeting HER2. Early gene expression microarray studies quickly identified ER positive (luminal), HER2-enriched and ER/HER2 negative (basal or basal-like; for simplicity I will use the term basal) groups (Perou et al, 2000; Sorlie et al, 2001; Sorlie et al, 2003) . To make the procedure more robust, the authors subsequently chose a fixed set of 50 genes and defined reference centroids that now form the basis of the widely used "PAM50" classification of breast cancer (Parker et al, 2009 ). In addition to basal and HER2-enriched groups, the PAM50 classification splits the luminal group into low and high proliferation groups (luminal A and B, respectively), and tumours that can not be distinguished from normal tissue are assigned to a "normal" group. An additional "claudin-low" group resembling cell lines that have undergone an epithelial-to-mesenchymal transition (EMT) was added later (Herschkowitz et al, 2007; Prat et al, 2010) .
In 2005 we performed a gene expression study on Affymetrix microarrays that found three main groups: basal, luminal and molecular apocrine (Farmer et al, 2005) .
Our luminal group merges the luminal groups from the PAM50; the basal group is essentially identical in the two classifications. The major disagreement concerns the HER2-enriched and molecular apocrine groups. In the PAM50 it was named "HER2-enriched" because many of the tumours were HER2 amplified. However, about onethird of HER2-enriched tumours are not HER2 amplified, and HER2 amplification is frequently observed in luminal B, occasionally in luminal A and rarely in basal tumours, as recently emphasised in a comprehensive study of HER2 amplification by Daemen and Manning (Daemen & Manning, 2018) . In 2005 we suggested that a better name for the HER2-enriched group would be "molecular apocrine" (MA). We based this suggestion on the expression of the androgen receptor (AR) and some genes commonly expressed in prostate cancer, and on the presence of apocrine histological features. We proposed that the tumours in this group were luminal tumours that had undergone apocrine metaplasia. Apocrine metaplasia is a common condition in normal breast tissue in which cells revert from an oestrogen-driven, mammary fate to their ancestral androgen-driven, apocrine fate. Other groups quickly confirmed the existence of a putative androgen-driven group in breast cancer gene ! 3! expression data (Doane et al, 2006; Guedj et al, 2012; Lehmann et al, 2011) . This hypothesis led oncologists to perform clinical trials with anti-androgens (Bonnefoi et al, 2016; Gucalp et al, 2013; Traina et al, 2018) . The clinical benefit rate observed in those trials was only 19-25%. While this may seem low, it is comparable to the clinical benefit rate to anti-oestrogen treatment (24-37%) used as second line therapy for ER-positive tumours (Smith & Dowsett, 2003) . A further reason for the modest efficacy of anti-androgens in the molecular apocrine trials may have been the inclusion of classic luminal tumours in the groups that received anti-androgens. The key problem leading to misclassification and thus suboptimal treatment is the lack of a precise definition of molecular apocrine tumours.
To go beyond descriptive arguments based on signatures the goal here is to implement a definition for molecular apocrine tumours based on the following explicit biological hypothesis: a molecular apocrine tumour is a hormone sensing cell tumour that has undergone apocrine metaplasia. In the normal mammary gland, luminal progenitors differentiate to form milk secreting cells (M) and hormone sensing cells (H , Fig 1) . Recent lineage tracing studies from the Blanpain and Guo groups have identified potential ER-positive stem cells that can maintain the ER-positive lineage through multiple rounds of grafting !(Van Keymeulen et al, 2017; Wang et al, 2017) .
This ER-positive stem cell (marked "H" in Fig 1) is potentially the cell of origin of human luminal and molecular tumours. Upon malignant transformation, I propose that ER-positive stem cells occasionally undergo apocrine metaplasia, lose ER expression and give rise to molecular apocrine tumours. Lineage tracing has also identified an ER-negative Notch1-derived cell that is potentially the cell of origin of human basal tumours (marked "M" in Fig 1) (Rodilla et al, 2015) . Unlike the classic Lim model (Lim et al, 2009) , the model in Fig 1 places basal tumours distal to luminal progenitors on the secretory branch because luminal progenitors express ER and ELF5, whereas basal tumours are rigorously ER-negative. The model explicitly states that molecular apocrine tumours are a subtype of hormone sensing cell tumour (Fig   1) .
The first step in the classification (the "luminal progenitor split") is based on expression of transcription factors that are known or suspected to play a role in defining secretory or sensory cell identity. The master regulator for the secretory lineage is ELF5 (Kalyuga et al, 2012; Oakes et al, 2008; Zhou et al, 2005) , and for the sensory lineage it is ER (Curtis Hewitt et al, 2000; Mallepell et al, 2006) , but they cooperate with other transcription factors that are themselves closely linked to cell fate. The first step in the classification is thus to split tumours into sensory cell tumours expressing ESR1, AR, FOXA1, TOX3, SPDEF, GATA3, MYB, MSX2, ! 4! TFAP2B and ESRRG; and secretory cell tumours expressing FOXC1, BCL11A, ELF5, KLF5, VGLL1, NFIB, ID4, SOX10 and EN1. These transcription factors show strongly bimodal expression in breast tumours allowing clean separation of the two cell types. They were selected based on published studies on mammary development, hormonal signalling and differential expression in normal and transformed mammary epithelial cells. MSX2 and BCL11A are directly implicated in defining mammary cell identity at the earliest stages of mammary gland development (Howard & Ashworth, 2006; Khaled et al, 2015) . ELF5, the master regulator of lactation, is necessary for the formation of milk secreting cells (Oakes et al, 2008; Zhou et al, 2005) . ER, AR, FOXA1 and GATA3 play crucial roles in the transcriptional response to androgens and oestrogens (Carroll et al, 2005; Robinson et al, 2011) . Some factors, like SPDEF, TOX3 and KLF5, are probably responsible for specific subprograms that contribute to mammary cell function! (Oishi et al, 2008; Raap et al, 2018; Seksenyan et al, 2015) . Others, like VGLL1, EN1 and SOX10, are components of classic developmental pathways (Loomis et al, 1996; Tsurusaki et al, 2014; Vaudin et al, 1999) . Translocation of MYB to NFIB perturbs mammary lineage decisions, resulting in the formation of adenoid cystic tumours with distinct luminal and myoepithelial tumour cell populations (Persson et al, 2009) . Many of these genes are known to be differentially expressed in purified mammary cell subsets (Asselin-Labat et al, 2007; Kendrick et al, 2008) .
The second step is to split sensory cell tumours into classic ER+ luminal tumours and molecular apocrine tumours. The critical underlying event is apocrine metaplasia accompanied by loss of ER expression but the biological mechanism is not currently understood; the working model is that an epigenetic event switches the cell between mammary and apocrine programs. The difference between these programs is that the former is regulated by oestrogens and the latter by androgens.
Since AR itself is expressed by both luminal and apocrine cells it can not be used to make the distinction. Pending greater understanding of the underlying epigenetic event the most useful marker is ER. I therefore created luminal and apocrine scores based on genes with the strongest positive and negative correlation with ESR1, respectively, using gene expression data (Farmer 2005; Farmer 2009 ) generated from a subset of tumours from the EORTC 10994 trial (Bonnefoi et al, 2011) . Only sensory cell tumours (luminal and molecular apocrine) were included in the subset 
METHODS
The EORTC 10994 phase III clinical trial tested whether p53 mutant tumours respond better to anthracycline-based chemotherapy that includes taxanes (Bonnefoi et al, 2011) . The trial was registered with ClinicalTrials.gov number NCT00017095 and approved by national and/or local ethics committees in all participating centres.
Before registration, all patients signed an informed consent for the trial and for research on tumour samples. Microarray data from 186 tumours included in our previous gene expression studies (Farmer et al, 2009; Farmer et al, 2005) , was downloaded from the NCBI GEO database entries with accession numbers GSE1561 and GSE6861. The batches and sample names in the GSE1561 study (49 samples) and GSE6861 study (161 samples) are given in Sup Table 1 .
The EORTC 10994 trial enrolled patients with T2-T4 M0 tumours with ≥20% tumour cells in the pretreatment biopsy. The RNA was extracted from a 200 um thickness of a 14G needle biopsy. The small size of the samples reduced the scope for tumour content to drift between the section examined by the pathologist and the material tested on the microarray. This may explain the rather low normal tissue contamination compared to studies using surgical samples. The tumours arrayed are not a random selection of tumours in the EORTC 10994 clinical study; instead they contain more ER-tumours leading to a more equal representation of luminal, molecular apocrine and basal tumours than in studies like TCGA (TCGA, 2012) which are overwhelmingly ER+.
To reduce overfitting to a single chip type, the data from the two EORTC 10994 microarray studies (GSE1561 and GSE6861) were pooled. GSE1561 was performed on Affymetrix U133A chips; GSE6861 was performed on Affymetrix X3P chips. The probesets in the former lie within 600 bp of the polyadenylation site, those in the latter within 300 bp of the polyadenylation site. The two datasets were combined with COMBAT (R sva package, Johnson et al, 2007) 
RESULTS

The LAB classification of breast tumours
The first step in the LAB classification of breast tumours is to split tumours into sensory cell (H) versus secretory cell (M) tumours (Fig1) based on the expression of transcription factors known or suspected to play an important role in defining mammary cell identity. I defined sensory and secretory scores as the mean expression values of the respective cell identity transcription factors after scaling.
The EORTC tumours form two clearly distinct clusters based on the sensory and secretory scores (Fig 2a) , yielding a strongly bimodal luminal progenitor score after 45° rotation of the data (Fig 2b&c) . I modelled the luminal progenitor scores as a mixture of normal distributions and defined a cut-off to distinguish the two tumour types (Fig 2d) and normalised the scores to place the peaks at -1 and 1 (Fig 2e) . and half negative (molecular apocrine) correlation. The genes are listed in Table 1. The classification procedure was then repeated exactly as for the luminal progenitor scores (Fig 2, lower panels) . The luminal-apocrine score is less bimodal than the luminal progenitor score, leading to greater overlap of the luminal and apocrine distributions. The distance to the grey zone is consequently only 1.4 times the standard deviation, indicating that only about 90% of tumours are likely to be correctly classified. The LAB class assignments are shown in Table 2 : 29% luminal, 23% molecular apocrine, 42% basal and 6% unknown. The bias towards molecular apocrine and basal tumours is expected because the samples chosen for the EORTC microarray studies were deliberately enriched in ER-negative tumours.
Application to an independent dataset
To test whether the LAB classification can be applied to other types of gene expression data the procedure was repeated on RNA-seq data from The Cancer Genome Atlas (TCGA, 2012) . (Table 3: 70% luminal, 7% molecular apocrine, 17% basal, 5% unknown). The high percentage of ER-positive tumours in the TCGA dataset is typical of breast cancer in the general population. It is difficult to give a precise figure for the expected fraction of molecular apocrine tumours in an unselected population but a figure of 7% is plausible. For example, a large French microarray study recently classified 11% of tumours as molecular apocrine (Guedj et al, 2012) . Hierarchical clustering shows the expected patterns: a homogeneous basal group, a small core molecular apocrine group and a large luminal group (Sup Fig 2; the red, pink and blue bars at the top of the heatmap show the LAB and PAM50 ! 8! classifications). I conclude that it is technically feasible to transfer the LAB classification across platforms and studies.
Comparison with the PAM50 classification
For the EORTC tumours, 43 of the PAM50 genes were successfully mapped to the Affymetrix dataset (the missing genes are not present on the U133A chip).
Nineteen tumours were incomparable (classified as Normal by PAM50, or unknown by LAB), leaving 191 samples to compare (Table 2) 
Comparison with two-gene predictors
Pathologists commonly use ER, AR and HER2/ERBB2 to identify molecular apocrine tumours. To explore the potential utility of these genes to define molecular apocrine status the expression of ER vs ERBB2 and ER vs AR in the EORTC and TCGA datasets was plotted (Fig 4, left and show that AR alone is not a good way to classify the tumours, with many luminal tumours having AR expression overlapping with that of molecular apocrine and basal tumours. FOXA1 is more bimodal than AR (Fig 5) . It produces three distinct clusters that correspond well to the LAB classification (Fig 4a&c) (Zhao et al, 2015) .
Approaches based on biology should be less sensitive to these issues. Indeed, it was surprisingly easy to transfer the LAB classification to RNA-seq data. It should be noted, however, that the LAB algorithm automatically reduces differences between datasets in a manner that would not meet the criteria for a universal clinical test. In particular, bimodal decomposition of the distribution of the scores to find the cut-off is sensitive to the composition of the dataset. Once the thresholds for a particular platform have been defined it should be easy to apply the algorithm on a case-bycase basis but that was not the goal of this study.
To verify that the LAB approach generates results that are broadly consistent with existing approaches it was compared to the widely used PAM50 test (Parker et al, 2009) . In considering the results it is important to note that the two approaches have different objectives. The PAM50 classifier encompasses proliferation, ER status, HER2 status and normal tissue contamination. The focus of the LAB classifier is to separate tumours based on an underlying biological model, not to measure proliferation or normal tissue contamination. There was excellent agreement in both the EORTC and TCGA datasets over the identification of luminal and basal tumours.
Where the two classifications were expected to disagree is over the HER2-enriched and molecular apocrine groups, and this is indeed what happened. The difficulty of distinguishing luminal B from HER2-enriched tumours in the PAM50 classification has been widely commented on (Farmer et al, 2005; Mackay et al, 2011; Weigelt et al, 2011) , including by the original authors of the PAM50 classification (Parker et al, 2009 ). In some cases the tumours in the luminal cluster called as HER2-enriched had increased ERBB2 expression. This is broadly expected because the main determinant of HER2-enriched status in the PAM50 classification is expression of two genes in the ERBB2 amplicon (ERBB2 and GRB7). Since ERBB2 is commonly amplified in luminal ER-positive tumours, it is inevitable that some luminal tumours will be misclassified as HER2-enriched. The root cause of the problem is that gene expression arrays measure phenotype not genotype. ERBB2 amplification is a DNA change (ie, genotype) that is seen in many tumour types that do not have a molecular apocrine phenotype! (Daemen & Manning, 2018) . There is an excellent correlation between ERBB2 amplification and ERBB2 expression, but it contributes only a small part to the molecular apocrine phenotype. This, and the fact that ERBB2 is amplified in both luminal and molecular apocrine tumours, make it an unreliable marker for molecular apocrine tumours. This explains why ERBB2 is not present in the gene list used for the luminal-apocrine split.
Unlike the PAM50, the LAB classification contains an "unknown" category.
This reflects the reality that some tumours resemble intermediate states, perhaps because some oncogenes induce plasticity that allows tumour cells to change identity (Koren et al, 2015; Van Keymeulen et al, 2015) . Whether to assign all tumours to a tumour class, as in the PAM50 classification, or to accept that some can not be classified, as in the LAB classification, is a philosophical question. In the PAM50 a tumour is given the class of the reference centroid to which it shows the highest correlation. An extreme example would be a tumour with a correlation of 0.50 to the normal centroid and a correlation of 0.51 to the luminal A centroid. In that case the coefficient of determination (r 2 ) differs by only 1% between the two assignments, meaning the decision is based on only 1% of the information in the profiles.
Clinicians faced with binary decisions (treatment A vs treatment B) may prefer always to receive a tumour class, even when they know it is based on imperfect information. If that were the goal it would be easy to remove the unknown group in the LAB classification. Tables   Table 1. LA genes. These genes were used to split luminal tumours from molecular apocrine tumours in the lower panels in Figs 
